Reported Earnings • Aug 13
First quarter 2027 earnings released First quarter 2027 results: Revenue: ₹500.8m (up 316% from 1Q 2026). Net income: ₹2.60m (down 79% from 1Q 2026). Profit margin: 0.5% (down from 10% in 1Q 2026). The decrease in margin was driven by higher expenses. Announcement • Aug 03
Genpharmasec Limited to Report Q1, 2027 Results on Aug 11, 2026 Genpharmasec Limited announced that they will report Q1, 2027 results on Aug 11, 2026 Reported Earnings • May 23
Full year 2026 earnings released: EPS: ₹0.01 (vs ₹0.022 in FY 2025) Full year 2026 results: EPS: ₹0.01. Revenue: ₹1.43b (up 324% from FY 2025). Net income: ₹16.0m (up 30% from FY 2025). Profit margin: 1.1% (down from 3.7% in FY 2025). The decrease in margin was driven by higher expenses. Announcement • May 13
Genpharmasec Limited to Report Q4, 2026 Results on May 21, 2026 Genpharmasec Limited announced that they will report Q4, 2026 results on May 21, 2026 New Risk • Mar 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹609.1m market cap, or US$6.59m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). Reported Earnings • Feb 10
Third quarter 2026 earnings released: ₹0.02 loss per share (vs ₹0.013 profit in 3Q 2025) Third quarter 2026 results: ₹0.02 loss per share (down from ₹0.013 profit in 3Q 2025). Revenue: ₹408.1m (up 381% from 3Q 2025). Net loss: ₹4.31m (down 155% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings. Announcement • Feb 02
Genpharmasec Limited to Report Q3, 2026 Results on Feb 09, 2026 Genpharmasec Limited announced that they will report Q3, 2026 results on Feb 09, 2026 Reported Earnings • Nov 09
Second quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.014 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.01 (down from ₹0.014 in 2Q 2025). Revenue: ₹331.0m (up 449% from 2Q 2025). Net loss: ₹11.8m (down 267% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. New Risk • Nov 03
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹886.0m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹886.0m market cap, or US$9.98m). Minor Risk Revenue is less than US$5m (₹406m revenue, or US$4.6m). Announcement • Oct 27
Genpharmasec Limited to Report Q2, 2026 Results on Nov 06, 2025 Genpharmasec Limited announced that they will report Q2, 2026 results on Nov 06, 2025 Announcement • Sep 03
Genpharmasec Limited, Annual General Meeting, Sep 29, 2025 Genpharmasec Limited, Annual General Meeting, Sep 29, 2025, at 11:00 Indian Standard Time. Reported Earnings • Aug 08
First quarter 2026 earnings released: EPS: ₹0.02 (vs ₹0.01 in 1Q 2025) First quarter 2026 results: EPS: ₹0.02 (up from ₹0.01 in 1Q 2025). Revenue: ₹127.4m (up 145% from 1Q 2025). Net income: ₹12.2m (up 324% from 1Q 2025). Profit margin: 9.5% (up from 5.5% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Announcement • Aug 02
Genpharmasec Limited to Report Q1, 2026 Results on Aug 07, 2025 Genpharmasec Limited announced that they will report Q1, 2026 results on Aug 07, 2025 Reported Earnings • May 22
Full year 2025 earnings released: EPS: ₹0.01 (vs ₹0.004 loss in FY 2024) Full year 2025 results: EPS: ₹0.01 (up from ₹0.004 loss in FY 2024). Revenue: ₹367.8m (up 21% from FY 2024). Net income: ₹12.3m (up ₹13.6m from FY 2024). Profit margin: 3.3% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Announcement • May 13
Genpharmasec Limited to Report Q4, 2025 Results on May 21, 2025 Genpharmasec Limited announced that they will report Q4, 2025 results on May 21, 2025 Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹2.33, the stock trades at a trailing P/E ratio of 78.3x. Average trailing P/E is 27x in the Trade Distributors industry in India. Total loss to shareholders of 39% over the past three years. Reported Earnings • Feb 12
Third quarter 2025 earnings released Third quarter 2025 results: EPS: ₹0.01. Revenue: ₹93.0m (up 46% from 3Q 2024). Net income: ₹7.80m (up ₹7.16m from 3Q 2024). Profit margin: 8.4% (up from 1.0% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Announcement • Feb 03
Genpharmasec Limited to Report Q3, 2025 Results on Feb 10, 2025 Genpharmasec Limited announced that they will report Q3, 2025 results on Feb 10, 2025 New Risk • Jan 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 6.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Minor Risks Profit margins are more than 30% lower than last year (3.1% net profit margin). Revenue is less than US$5m (₹278m revenue, or US$3.2m). Market cap is less than US$100m (₹1.32b market cap, or US$15.3m). Reported Earnings • Nov 14
Second quarter 2025 earnings released Second quarter 2025 results: EPS: ₹0.01. Revenue: ₹67.8m (down 14% from 2Q 2024). Net income: ₹7.04m (up ₹6.96m from 2Q 2024). Profit margin: 10% (up from 0.1% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 25% per year. Announcement • Nov 05
Genpharmasec Limited to Report Q2, 2025 Results on Nov 12, 2024 Genpharmasec Limited announced that they will report Q2, 2025 results on Nov 12, 2024 New Risk • Sep 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (93% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin). Revenue is less than US$5m (₹296m revenue, or US$3.5m). Market cap is less than US$100m (₹1.70b market cap, or US$20.3m). Reported Earnings • Aug 14
First quarter 2025 earnings released First quarter 2025 results: EPS: ₹0.01. Revenue: ₹57.6m (down 3.4% from 1Q 2024). Net income: ₹2.87m (up ₹2.61m from 1Q 2024). Profit margin: 5.0% (up from 0.4% in 1Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 32% per year whereas the company’s share price has fallen by 35% per year. Announcement • Aug 05
Genpharmasec Limited to Report Q1, 2025 Results on Aug 13, 2024 Genpharmasec Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Announcement • Jun 28
Genpharmasec Limited, Annual General Meeting, Jul 23, 2024 Genpharmasec Limited, Annual General Meeting, Jul 23, 2024, at 11:00 Indian Standard Time. Announcement • Mar 28
Genpharmasec Limited Announces Appointment of Hardik Makwana as Company Secretary & Compliance Officer Genpharmasec Limited at its board meeting held on March 27, 2024, Mr. Hardik Makwana (Membership. No.: A72702) has been appointed by the Board as a Company Secretary & Compliance Officer of the Company effective 27 March 2024, in their Board Meeting based on the recommendation of Nomination & Remuneration Committee. Announcement • Mar 21
Genpharmasec Limited Announces Resignation of Heta Shah as Company Secretary / Compliance Officer Genpharmasec Limited informed that Ms. Heta Shah, Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company has tendered his resignation from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company vide her letter dated 20% March, 2024 and will be relieved from the services of the Company effective the close of business hours on 20% March, 2024 due to her pre-occupation elsewhere. Due to her Pre-occupation elsewhere, Ms. Heta Shah, Company Secretary and Compliance Officer has served her resignation from the post of Company Secretary and Compliance Officer (Key Managerial Personnel) to the Company effective 20th March, 2024. New Risk • Feb 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 100% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₹264m revenue, or US$3.2m). Market cap is less than US$100m (₹2.23b market cap, or US$26.9m). Announcement • Feb 15
Genpharmasec Limited has completed a Follow-on Equity Offering in the amount of INR 484.504738 million. Genpharmasec Limited has completed a Follow-on Equity Offering in the amount of INR 484.504738 million.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 276,859,850
Price\Range: INR 1.75
Transaction Features: Regulation S; Rights Offering Reported Earnings • Feb 13
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: ₹65.3m (up 1.9% from 3Q 2023). Net income: ₹634.0k (down 73% from 3Q 2023). Profit margin: 1.0% (down from 3.7% in 3Q 2023). The decrease in margin was driven by higher expenses. Announcement • Feb 06
Genpharmasec Limited to Report Q3, 2024 Results on Feb 12, 2024 Genpharmasec Limited announced that they will report Q3, 2024 results on Feb 12, 2024 New Risk • Nov 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (39% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Revenue is less than US$5m (₹264m revenue, or US$3.2m). Market cap is less than US$100m (₹1.41b market cap, or US$16.9m). Reported Earnings • Nov 10
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: ₹80.1m (up 33% from 2Q 2023). Net income: ₹79.0k (down 88% from 2Q 2023). Profit margin: 0.1% (down from 1.1% in 2Q 2023). The decrease in margin was driven by higher expenses. Announcement • Sep 21
Genpharmasec Limited (BSE:531592) signed a share purchase agreement to acquire an unknown stake in Derren Healthcare Private Limited from the existing shareholder for approximately INR 130 million. Genpharmasec Limited (BSE:531592) signed a share purchase agreement to acquire an unknown stake in Derren Healthcare Private Limited from the existing shareholder for approximately INR 130 million on September 19, 2023. In a related transaction, Genpharmasec signed a share subscription cum shareholder’s agreement to subscribe stake in Derren Healthcare over a period of 1 year in phased manner. Consequenlly, Genpharmasec shall own 70% of the stake of Derren Healthcare. Derren Healthcare reported turnover of INR 7.2 million for the year ended March 31, 2023. The transaction is expected to complete within one year. Announcement • Sep 02
Genpharmasec Limited, Annual General Meeting, Sep 23, 2023 Genpharmasec Limited, Annual General Meeting, Sep 23, 2023, at 09:30 Indian Standard Time. Location: Kriish Cottage, C-101/201, Manas Building Near St lawrence high school, devidas lane, borivali (WEST) Mumbai Maharashtra India Agenda: To receive, consider and adopt the Audited Financial Statements of the Company for the year 2022-2023 including Audited Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss and Cash Flow Statement for the year ended on that date and the Reports of the Board of Directors and Auditors thereon; to Re-Appointment of Mr. Rajesh Sadhwani as a director liable to retire by rotation; to To consider and determine the fees for delivery of any document. Reported Earnings • Aug 13
First quarter 2024 earnings released First quarter 2024 results: Revenue: ₹59.6m (down 13% from 1Q 2023). Net income: ₹261.0k (up ₹2.40m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). The move to profitability was driven by lower expenses. Announcement • Aug 04
Genpharmasec Limited to Report Q1, 2024 Results on Aug 11, 2023 Genpharmasec Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Announcement • May 19
Genpharmasec Limited to Report Q4, 2023 Results on May 26, 2023 Genpharmasec Limited announced that they will report Q4, 2023 results on May 26, 2023 Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.01 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.01 (in line with 3Q 2022). Revenue: ₹64.2m (down 5.0% from 3Q 2022). Net income: ₹2.36m (up 6.9% from 3Q 2022). Profit margin: 3.7% (up from 3.3% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 37 percentage points per year, which is a significant difference in performance. Announcement • Feb 03
Genpharmasec Limited to Report Q3, 2023 Results on Feb 10, 2023 Genpharmasec Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 10, 2023 Announcement • Nov 05
Genpharmasec Limited to Report Q2, 2023 Results on Nov 11, 2022 Genpharmasec Limited announced that they will report Q2, 2023 results on Nov 11, 2022 Announcement • Oct 08
Genpharmasec Limited Appoints Heta Shah as Company Secretary and Compliance Officer, with Effect from October 7, 2022 Genpharmasec Limited appointed Mrs. Heta Shah (having Membership No.: A69749), as Company Secretary & Compliance Officer from 7th October 2022. Announcement • Oct 07
Genpharmasec Limited Announces Resignation of Amisha Mitesh Dani as Independent Director Genpharmasec Limited announced that Mrs. Amisha Mitesh Dani, Independent Director has served her resignation from the post of Independent Director to the Company, effective 04th October 2022. The disclosures as required under Part A of Schedule III of Securities and Exchange Board of India. Announcement • Sep 07
Genpharmasec Limited, Annual General Meeting, Sep 29, 2022 Genpharmasec Limited, Annual General Meeting, Sep 29, 2022, at 09:30 Indian Standard Time. Location: Kriish Cottage, C-101/201 Manas Building, Near St. Lawrence High School Devidas Lane, Borivali (West), Mumbai 400103 Mumbai India Agenda: To receive, consider and adopt the Audited Financial Statements of the Company for the year 2022 including Audited Balance Sheet as at 31st March, 2022, the Statement of Profit and Loss and Cash Flow Statement for the year ended on that date and the Reports of the Board of Directors and Auditors thereon; to consider appointment of Mr. Ulhas Narayan Deosthale (DIN: 09215291) as a director liable to retire by rotation: and to consider other matters. Reported Earnings • Aug 12
First quarter 2023 earnings released: ₹0.01 loss per share (vs ₹0.01 profit in 1Q 2022) First quarter 2023 results: ₹0.01 loss per share (down from ₹0.01 profit in 1Q 2022). Revenue: ₹69.0m (down 15% from 1Q 2022). Net loss: ₹2.14m (down 247% from profit in 1Q 2022). Announcement • Jul 05
Genpharmasec Limited Announces Executive Appointments Genpharmasec Limited appointed Sohan Chaturvedi and Siddhesh Shende as additional and Non- Executive Independent Director effective from July 04, 2022. Announcement • Jun 22
Genpharmasec Limited Announces Director Resignations with Effect from June 21, 2022 Genpharmasec Limited announced Director resignations with effect from June 21, 2022. Mr. Yogesh Bhuva (DIN: 09293985) resigned as a Non-Executive Independent Director from the Board of Directors. Ms. Nikhita Pais (DIN: 09271906) resigned as a Non- Executive Independent Director from the Board of Directors. Announcement • Jun 19
Genpharmasec Limited Announces Resignation of Independent Directors Genpharmasec Limited announced that it have received intimation from Mr. Yogesh Bhuva and Ms. Nikhita Pais about their resignation from the post of Non-Executive Independent Director of the company. Reported Earnings • May 30
Full year 2022 earnings released: ₹0.01 loss per share (vs ₹0.046 profit in FY 2021) Full year 2022 results: ₹0.01 loss per share (down from ₹0.046 profit in FY 2021). Revenue: ₹274.1m (up 29% from FY 2021). Net loss: ₹2.09m (down 117% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Announcement • May 19
Genpharmasec Limited to Report Q4, 2022 Results on May 27, 2022 Genpharmasec Limited announced that they will report Q4, 2022 results on May 27, 2022 Reported Earnings • Feb 17
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.01. Revenue: ₹67.8m (up 181% from 3Q 2021). Net income: ₹2.20m (up ₹1.97m from 3Q 2021). Profit margin: 3.3% (up from 1.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • Feb 16
Genpharmasec Limited Announces Resignation of Vivek Anand Oberoi as Chief Strategy Officer Genpharmasec Limited announced that at its board meeting held on February 14, 2022, approved resignation of Mr. Vivek Anand Oberoi, from the post of chief strategy officer of the company, effective February 14, 2022 due to his pre-occupation in other assignments. Board Change • Nov 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non Executive Independent Director Amisha Dani is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Oct 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non Executive Independent Director Amisha Dani is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Executive Departure • Sep 09
Additional Non-Executive Independent Director Sachin Aphandkar has left the company On the 6th of September, Sachin Aphandkar's tenure as Additional Non-Executive Independent Director ended after 1.5 years in the role. We don't have any record of a personal shareholding under Sachin's name. A total of 3 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model. Board Change • Sep 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non Executive Independent Director Amisha Dani is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Aug 18
First quarter 2022 earnings released: EPS ₹0.01 The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹81.6m (down 1.0% from 1Q 2021). Net income: ₹1.45m (down 85% from 1Q 2021). Profit margin: 1.8% (down from 11% in 1Q 2021). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Executive Departure • Aug 18
Non Executive Independent Director Veda Bhushan has left the company On the 12th of August, Veda Bhushan's tenure as Non Executive Independent Director ended after 6.4 years in the role. We don't have any record of a personal shareholding under Veda's name. A total of 2 executives have left over the last 12 months. Reported Earnings • Jul 04
Full year 2021 earnings released: EPS ₹0.05 (vs ₹0.047 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: ₹216.4m (up 31% from FY 2020). Net income: ₹12.6m (up 25% from FY 2020). Profit margin: 5.8% (down from 6.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 22
New 90-day low: ₹9.05 The company is down 26% from its price of ₹12.17 on 24 November 2020. The Indian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Trade Distributors industry, which is up 79% over the same period. Reported Earnings • Feb 12
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹24.1m (down 2.8% from 3Q 2020). Net income: ₹238.0k (down 77% from 3Q 2020). Profit margin: 1.0% (down from 4.2% in 3Q 2020). Announcement • Feb 03
Generic Pharmasec Limited to Report Q3, 2021 Results on Feb 10, 2021 Generic Pharmasec Limited announced that they will report Q3, 2021 results on Feb 10, 2021 Is New 90 Day High Low • Jan 12
New 90-day low: ₹9.96 The company is down 24% from its price of ₹13.05 on 14 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Trade Distributors industry, which is up 59% over the same period. Is New 90 Day High Low • Dec 23
New 90-day low: ₹10.30 The company is down 4.0% from its price of ₹10.71 on 24 September 2020. The Indian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Trade Distributors industry, which is up 42% over the same period. Is New 90 Day High Low • Dec 03
New 90-day high: ₹13.09 The company is up 20% from its price of ₹10.87 on 04 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Trade Distributors industry, which is up 35% over the same period. Announcement • Nov 29
Generic Pharmasec Limited, Annual General Meeting, Dec 22, 2020 Generic Pharmasec Limited, Annual General Meeting, Dec 22, 2020. Is New 90 Day High Low • Sep 29
New 90-day low: ₹10.39 The company is down 11% from its price of ₹11.70 on 01 July 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Trade Distributors industry, which is up 58% over the same period. Announcement • Aug 30
Generic Pharmasec Limited to Report Q1, 2021 Results on Sep 07, 2020 Generic Pharmasec Limited announced that they will report Q1, 2021 results on Sep 07, 2020 
